PGR and neoplasm: At the multivariable analyses (Table 2), after adjusting for age, menopausal status, tumour size, lymph node status, grading, proliferative activity and oestrogen and progesterone receptor status, no significant difference was observed in OS (HR = 0.89, 95% CI: 0.72–1.09; p = 0.26) or EFS (HR = 0.87, 95% CI: 0.73–1.05; p = 0.14) between FEC21 and FEC14 regimen.